Clinical Trial Update: Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of docetaxel and pembrolizumab for head and neck squamous cell carcinoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Hokkaido University Hospital | Conditions: Effect of Drug | Phase 2 | Status: ACTIVE_NOT_RECRUITING